This dose-ranging study is an ongoing 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study designed to evaluate the safety and efficacy of upadacitinib in adult patients with moderate to severe
atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable.
Demonstrate an understanding of how
atopic dermatitis can affect patient sleep, quality of life, daily activities, risk of comorbidities, and health care utilization/cost
High proportions of patients with moderate to severe
atopic dermatitis reported experiencing dry, rough skin (91%), flaking skin (77.
We are extremely pleased with the outcome of this study where clinically meaningful differences were observed not just in the symptom of the worst itch in patients suffering from
atopic dermatitis but also in measures of disease severity.
Another promising agent for
atopic dermatitis is 2% crisaborole topical ointment, a boron-based PDE-4 inhibitor developed by Anacor Pharmaceuticals.
aureus is one of the most powerful triggers for
atopic dermatitis "flares," the period of time when the condition gets worse, which is then followed by a period of remission.
The report reviews key players involved
Atopic dermatitis therapeutics and enlists all their major and minor projects
Caption:
Atopic dermatitis (above) does not up AK risk.
The
Atopic Dermatitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
How epidemiology has challenged 3 prevailing concepts about
atopic dermatitis.
EpiCast Report:
Atopic Dermatitis - Epidemiology Forecast to 2022
In the present study, the prevalence of
atopic dermatitis among various dermatoses in dogs were recorded as 21.
